The genotyping laboratory at the Pharmacogenomics Centre operates under Good Laboratory Practice/ Good Clinical Laboratory Practice (GLP/GCLP) standards and provides services to clients in the academic, industrial, and pharmaceutical communities. All operations are conducted following Standard Operating Procedures (SOP) and all experiments are documented in a Laboratory Information Management System (LIMS). The Centre offers different technologies for genotyping of SNPs (Single Nucleotide Polymorphisms), Indels (Insertion and deletion polymorphisms) and CNVs (Copy Number Variation).
Having been a close collaborator to the pharmaceutical industry for many years, the Pharmacogenomics Centre has developed a thorough expertise in assay validation respecting the highest quality standards required by regulatory agencies (CAP-CLIA, ISO). The validation level of custom and commercially available assays can be modulated on the nature and requirements of individual projects. As part of its core expertise, the Pharmacogenomics Centre also offers genotyping project evaluation and planning. The Pharmacogenomics Centre is a Agena Bioscience Certified Service Provider (CSP) in the area of genotyping on the Agena Bioscience platform.
Genotyping Core Expertise
- MassArray Custom Assay Development, Genotyping, Data Analysis and Complete Data Reporting (up to 400 loci) (link).
- iPLEX Chemistry
- LightCycler Custom Assay Development, Genotyping, Data Analysis and Complete Data Reporting (Up to 3 loci)
- TaqMan assay (link)
- Assay Validation
- Clinical grade assay validation (Accuracy, sensitivity, specificity, limit of detection, reproducibility, reportable range and reference range)
- Genome-Wide Association (GWAS) Genotyping, Data Analysis and Complete Data Reporting
- Illumina®Infinium HD (from 3,000 to 5M loci) (link)
- ADME (Absorption, Distribution, Metabolism and Excretion) genes genotyping, interpretation and detailed reporting on ADME genes activities
-
-
- Agena Veridose Core and Agena Veridose CNV
Gene SNP Variant ABCB1 rs1045642 3435C>T APOE rs429358 ε4 APOE rs7412 ε2 COMT rs4680 472G>A CYP1A2 rs12720461 *1K CYP1A2 rs2069514 *1C CYP1A2 rs56107638 *7 CYP1A2 rs72547513 *11 CYP1A2 rs762551 *1F CYP2B6 rs28399499 *18 CYP2B6 rs3745274 *6 CYP2C19 rs12248560 *17 CYP2C19 rs28399504 *4 CYP2C19 rs41291556 *8 CYP2C19 rs4244285 *2 CYP2C19 rs4986893 *3 CYP2C19 rs56337013 *5 CYP2C19 rs72552267 *6 CYP2C19 rs72558186 *7 CYP2C9 rs1057910 *3 CYP2C9 rs1799853 *2 CYP2C9 rs28371685 *11 CYP2C9 rs28371686 *5 CYP2C9 rs56165452 *4 CYP2C9 rs72558187 *13 CYP2C9 rs72558190 *15 CYP2C9 rs7900194 *8 CYP2C9 rs869277704 (rs72558188) *25 CYP2C9 rs9332131 *6 CYP2C9 rs9332239 *12 CYP2D6 dup4125_4133 *18 CYP2D6 rs28371735 *36 CYP2D6 rs28371706 *17 CYP2D6 rs5030865 *14 CYP2D6 rs5030865 *8 CYP2D6 rs72549354 *20 CYP2D6 rs3892097 *4 CYP2D6 rs1065852 *10 CYP2D6 rs1135840 *2 CYP2D6 rs16947 *2 CYP2D6 rs201377835 (rs5030863) *11 CYP2D6 rs28371725 *41 CYP2D6 rs35742686 *3 CYP2D6 rs5030655 *6 CYP2D6 rs5030656 *9 CYP2D6 rs5030862 *12 CYP2D6 rs5030867 *7 CYP2D6 rs59421388 *29 CYP2D6 rs72549353 *19 CYP2D6 rs774671100 (rs72549357) *15 CYP3A4 rs35599367 *22 CYP3A4 rs4987161 *17 CYP3A4 rs55785340 *2 CYP3A5 rs10264272 *6 CYP3A5 rs41303343 *7 CYP3A5 rs776746 *3 DRD2 rs1800497 Taq1A F2 rs1799963 p.G20210A F5 rs6025 p.R506Q GLP1R rs6923761 A risk allele GLP1R rs1042044 p.L260F GLP1R rs2300615 A risk allele MTHFR rs1801131 1286A>C MTHFR rs1801133 665C>T OPRM1 rs1799971 118 A>G PNPLA5 rs5764010 c.608-169G>A SLCO1B1 rs4149056 *5; *15 SULT4A1 rs763120 T risk allele VKORC1 rs9923231 *2 -
-
Contact
Ian Mongrain, M.Sc.
Directeur des opérations/Director of operations
Beaulieu-Saucier Pharmacogenomics Centre
Montreal Heart Institute, office S-2050
5000, Belanger East, Montreal
Qc, Canada, H1T1C8
Office: 514-670-7670, 7716
CA/USA: 1-855-670-7670, 7716
Fax: +1-514-670-7671